Inogen (NASDAQ:INGN) Downgraded by StockNews.com to “Hold”

StockNews.com cut shares of Inogen (NASDAQ:INGN) from a buy rating to a hold rating in a report published on Friday morning.

Separately, Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Friday, November 8th.

Inogen Trading Up 2.0 %

NASDAQ:INGN opened at $8.48 on Friday. The stock has a 50 day simple moving average of $9.46 and a 200 day simple moving average of $9.72. The stock has a market cap of $201.98 million, a P/E ratio of -3.77 and a beta of 1.02. Inogen has a 1-year low of $5.08 and a 1-year high of $13.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. bought a new stake in Inogen in the 2nd quarter valued at about $30,000. Quarry LP purchased a new stake in shares of Inogen during the 3rd quarter valued at $59,000. Verition Fund Management LLC bought a new stake in Inogen in the third quarter worth about $106,000. Virtu Financial LLC purchased a new position in Inogen in the third quarter valued at approximately $111,000. Finally, Paloma Partners Management Co purchased a new stake in Inogen in the 3rd quarter worth about $126,000. 89.94% of the stock is owned by institutional investors and hedge funds.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.